Riatlas – Oncology

RIATLAS ONCOLOGY

RiAtlas Oncology is a digital health solution developed as a Software as Medical Device (CE Class I), for the management, active monitoring and remote assistance of oncological patients who, after an acute phase, start a therapeutic and assistance pathway with frequent returns to the hospital (e.g. chemotherapy cycles) in the perspective of Continuity of Care (de-hospitalisation).
RiAtlas Oncology aims to support the clinical decisions of healthcare professionals and to improve the patients’ quality of life by promoting patient empowerment and active participation in their own care pathway.

DISTINCTIVENESS

Intelligent classification of the patient’s health status according to the World Health Organisation’s ICF classification.

Patient context data visualisation (symptoms/vital parameters) related to clinical data.

Alerting Systemand early detection of clinical risks based on Incremental Learning.

SOLUTION COMPONENTS

PATIENT MOBILE APP

Symptom (self-reported outcomes) and vital parameters collection, integrated with a wearable device (smartwatch) for automatic and real-time acquisition of vital parameters (heart rate, oxygenation, blood pressure, steps, etc.).

CLINICAL WEB APP

Management of patient care (e.g. health profile: lifestyle, medication, devices, health status, medical history); clinical evaluation/assessment (laboratory analysis, biomedical parameters, clinical rating scales, epicrisis, alarm management, etc.); remote monitoring of the care pathway, through the evaluation of symptoms/biomedical parameters, alarms and summary reports (dashboard/dashboard).

ARTIFICIAL INTELLIGENCE TOOL

Patient’s health status classification according to the ICF classification of the WHO

RiAtlas Healthcare is compliant with healthcare market standards, in terms of interoperability (HL7-FHIR),
certification (CE Class I medical device), privacy (GDPR) and security (OWASP).

CLINICAL VALIDATION

The RiAtlas Oncology solution, in its application to patients with colorectal cancer, has been tested and validated thanks to the participation in research and development projects conducted in collaboration with the Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale and the University of Campania Luigi Vanvitelli.

Clinical studies have shown a clinical concordance of over 90% with the suggestions provided by the Artificial Intelligence tool and the early detection of clinical risks, which has allowed the prompt modification of the therapy with the aim of improving the quality of life and care of patients.

The ease of use of the software solution has also demonstrated a level of usability and user acceptance greater than 95%, encouraging active patient participation in their care.

In addition, during the recent health emergency caused by the Covid-19 virus, the Istituto Tumori Pascale in Naples exploited the features and potential of the RiAtlas Oncology solution to create a remote monitoring system for coronavirus patients in home isolation. The data collected enabled immediate intervention when needed and highlighted the strong scalability of the solution to other types of pathology.